Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05412082 · ClinicalTrials.gov registry record · Phase 1
SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer
A Phase 1 study of Locally Advanced Rectal Cancer, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05412082 is a Phase 1 study of Locally Advanced Rectal Cancer that is actively recruiting participants, run by University of Miami. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05412082, a Phase 1 study of Locally Advanced Rectal Cancer, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to find out how safe and effective is treating patients with locally advanced rectal cancer (LARC) with chemotherapy first and then follow with radiation therapy to a higher dose than what is usually delivered and see if patients could have complete response and be spared from surgery.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG 5-fluorouracil
- RADIATION Intensity-modulated radiation therapy
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-10-05 |
| Est. Completion | 2028-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05412082
The ClinicalTrials.gov registry entry for NCT05412082 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced Rectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Capecitabine is the first listed.
NCT05412082 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05412082 about?
NCT05412082 is a clinical study titled "SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer". The purpose of this research study is to find out how safe and effective is treating patients with locally advanced rectal cancer (LARC) with chemotherapy first and then follow with radiation therapy to a higher dose than what is usually delivered and see if patients could have complete response and...
What is the current status of trial NCT05412082?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2022-10-05. Estimated completion is 2028-10-31.
What conditions does trial NCT05412082 study?
This clinical trial studies the following conditions: Locally Advanced Rectal Cancer.
What interventions are being tested in trial NCT05412082?
The interventions under investigation include: Capecitabine (DRUG), Leucovorin (DRUG), Oxaliplatin (DRUG), 5-fluorouracil (DRUG), Intensity-modulated radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT05412082?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05412082 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.